nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylphenidate—CYP2D6—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.00319	0.0884	CbGpPWpGaD
Methylphenidate—SLC6A2—Amine compound SLC transporters—SLC14A2—urinary bladder cancer	0.00292	0.0809	CbGpPWpGaD
Methylphenidate—SLC6A3—Amine compound SLC transporters—SLC14A2—urinary bladder cancer	0.00259	0.0716	CbGpPWpGaD
Methylphenidate—CYP2D6—Miscellaneous substrates—CYP4B1—urinary bladder cancer	0.00208	0.0575	CbGpPWpGaD
Methylphenidate—CYP2D6—Fatty acids—CYP4B1—urinary bladder cancer	0.00174	0.0481	CbGpPWpGaD
Methylphenidate—SLC6A3—Dopaminergic Neurogenesis—GLI1—urinary bladder cancer	0.00157	0.0434	CbGpPWpGaD
Methylphenidate—CYP2D6—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00147	0.0408	CbGpPWpGaD
Methylphenidate—CYP2D6—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.0012	0.0331	CbGpPWpGaD
Methylphenidate—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC14A2—urinary bladder cancer	0.00114	0.0316	CbGpPWpGaD
Methylphenidate—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC14A2—urinary bladder cancer	0.00101	0.028	CbGpPWpGaD
Methylphenidate—SLC6A4—NRF2 pathway—UGT2B7—urinary bladder cancer	0.000876	0.0243	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—UGT2B7—urinary bladder cancer	0.000753	0.0209	CbGpPWpGaD
Methylphenidate—SLC6A3—NRF2 pathway—UGT2B7—urinary bladder cancer	0.000667	0.0185	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—KMT2A—urinary bladder cancer	0.00063	0.0175	CbGpPWpGaD
Methylphenidate—SLC6A3—Parkinsons Disease Pathway—CCNE1—urinary bladder cancer	0.000597	0.0165	CbGpPWpGaD
Methylphenidate—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000573	0.0159	CbGpPWpGaD
Methylphenidate—CYP2D6—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000566	0.0157	CbGpPWpGaD
Methylphenidate—SLC6A2—SLC-mediated transmembrane transport—SLC14A2—urinary bladder cancer	0.000519	0.0144	CbGpPWpGaD
Methylphenidate—Asthenia—Cisplatin—urinary bladder cancer	0.000502	0.000521	CcSEcCtD
Methylphenidate—Pharyngitis—Epirubicin—urinary bladder cancer	0.000502	0.000521	CcSEcCtD
Methylphenidate—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000501	0.00052	CcSEcCtD
Methylphenidate—Sweating—Doxorubicin—urinary bladder cancer	0.0005	0.000518	CcSEcCtD
Methylphenidate—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000499	0.000518	CcSEcCtD
Methylphenidate—Haematuria—Doxorubicin—urinary bladder cancer	0.000497	0.000515	CcSEcCtD
Methylphenidate—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000497	0.000515	CcSEcCtD
Methylphenidate—Urethral disorder—Epirubicin—urinary bladder cancer	0.000496	0.000514	CcSEcCtD
Methylphenidate—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000493	0.000511	CcSEcCtD
Methylphenidate—Epistaxis—Doxorubicin—urinary bladder cancer	0.000491	0.00051	CcSEcCtD
Methylphenidate—Angiopathy—Methotrexate—urinary bladder cancer	0.00049	0.000508	CcSEcCtD
Methylphenidate—Sinusitis—Doxorubicin—urinary bladder cancer	0.000489	0.000507	CcSEcCtD
Methylphenidate—Immune system disorder—Methotrexate—urinary bladder cancer	0.000488	0.000506	CcSEcCtD
Methylphenidate—Dizziness—Fluorouracil—urinary bladder cancer	0.000488	0.000506	CcSEcCtD
Methylphenidate—Visual impairment—Epirubicin—urinary bladder cancer	0.000487	0.000505	CcSEcCtD
Methylphenidate—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000487	0.000505	CcSEcCtD
Methylphenidate—Chills—Methotrexate—urinary bladder cancer	0.000485	0.000503	CcSEcCtD
Methylphenidate—Diarrhoea—Cisplatin—urinary bladder cancer	0.000479	0.000496	CcSEcCtD
Methylphenidate—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000478	0.000496	CcSEcCtD
Methylphenidate—Alopecia—Methotrexate—urinary bladder cancer	0.000477	0.000495	CcSEcCtD
Methylphenidate—Vomiting—Gemcitabine—urinary bladder cancer	0.000477	0.000495	CcSEcCtD
Methylphenidate—Bradycardia—Doxorubicin—urinary bladder cancer	0.000476	0.000494	CcSEcCtD
Methylphenidate—Mental disorder—Methotrexate—urinary bladder cancer	0.000473	0.000491	CcSEcCtD
Methylphenidate—Rash—Gemcitabine—urinary bladder cancer	0.000473	0.000491	CcSEcCtD
Methylphenidate—Dermatitis—Gemcitabine—urinary bladder cancer	0.000473	0.00049	CcSEcCtD
Methylphenidate—Eye disorder—Epirubicin—urinary bladder cancer	0.000472	0.00049	CcSEcCtD
Methylphenidate—Hypersensitivity—Etoposide—urinary bladder cancer	0.000472	0.00049	CcSEcCtD
Methylphenidate—Malnutrition—Methotrexate—urinary bladder cancer	0.00047	0.000488	CcSEcCtD
Methylphenidate—Erythema—Methotrexate—urinary bladder cancer	0.00047	0.000488	CcSEcCtD
Methylphenidate—Haemoglobin—Doxorubicin—urinary bladder cancer	0.00047	0.000488	CcSEcCtD
Methylphenidate—Headache—Gemcitabine—urinary bladder cancer	0.00047	0.000488	CcSEcCtD
Methylphenidate—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000469	0.000487	CcSEcCtD
Methylphenidate—Flushing—Epirubicin—urinary bladder cancer	0.000469	0.000487	CcSEcCtD
Methylphenidate—Vomiting—Fluorouracil—urinary bladder cancer	0.000469	0.000487	CcSEcCtD
Methylphenidate—Rhinitis—Doxorubicin—urinary bladder cancer	0.000469	0.000487	CcSEcCtD
Methylphenidate—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000468	0.000485	CcSEcCtD
Methylphenidate—Rash—Fluorouracil—urinary bladder cancer	0.000465	0.000483	CcSEcCtD
Methylphenidate—Dermatitis—Fluorouracil—urinary bladder cancer	0.000465	0.000482	CcSEcCtD
Methylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000465	0.0129	CbGpPWpGaD
Methylphenidate—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000464	0.000482	CcSEcCtD
Methylphenidate—Headache—Fluorouracil—urinary bladder cancer	0.000462	0.000479	CcSEcCtD
Methylphenidate—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000462	0.000479	CcSEcCtD
Methylphenidate—Asthenia—Etoposide—urinary bladder cancer	0.00046	0.000477	CcSEcCtD
Methylphenidate—SLC6A3—SLC-mediated transmembrane transport—SLC14A2—urinary bladder cancer	0.00046	0.0127	CbGpPWpGaD
Methylphenidate—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.00046	0.000477	CcSEcCtD
Methylphenidate—Angiopathy—Epirubicin—urinary bladder cancer	0.000459	0.000476	CcSEcCtD
Methylphenidate—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000459	0.000476	CcSEcCtD
Methylphenidate—Immune system disorder—Epirubicin—urinary bladder cancer	0.000457	0.000474	CcSEcCtD
Methylphenidate—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000456	0.000473	CcSEcCtD
Methylphenidate—Back pain—Methotrexate—urinary bladder cancer	0.000455	0.000472	CcSEcCtD
Methylphenidate—Chills—Epirubicin—urinary bladder cancer	0.000454	0.000471	CcSEcCtD
Methylphenidate—Pruritus—Etoposide—urinary bladder cancer	0.000453	0.00047	CcSEcCtD
Methylphenidate—Arrhythmia—Epirubicin—urinary bladder cancer	0.000452	0.000469	CcSEcCtD
Methylphenidate—Visual impairment—Doxorubicin—urinary bladder cancer	0.000451	0.000468	CcSEcCtD
Methylphenidate—Alopecia—Epirubicin—urinary bladder cancer	0.000447	0.000463	CcSEcCtD
Methylphenidate—Nausea—Gemcitabine—urinary bladder cancer	0.000446	0.000462	CcSEcCtD
Methylphenidate—Vomiting—Cisplatin—urinary bladder cancer	0.000445	0.000461	CcSEcCtD
Methylphenidate—Vision blurred—Methotrexate—urinary bladder cancer	0.000443	0.00046	CcSEcCtD
Methylphenidate—Mental disorder—Epirubicin—urinary bladder cancer	0.000443	0.000459	CcSEcCtD
Methylphenidate—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000442	0.000459	CcSEcCtD
Methylphenidate—Rash—Cisplatin—urinary bladder cancer	0.000441	0.000457	CcSEcCtD
Methylphenidate—Dermatitis—Cisplatin—urinary bladder cancer	0.000441	0.000457	CcSEcCtD
Methylphenidate—Malnutrition—Epirubicin—urinary bladder cancer	0.00044	0.000457	CcSEcCtD
Methylphenidate—Erythema—Epirubicin—urinary bladder cancer	0.00044	0.000457	CcSEcCtD
Methylphenidate—Diarrhoea—Etoposide—urinary bladder cancer	0.000438	0.000455	CcSEcCtD
Methylphenidate—Nausea—Fluorouracil—urinary bladder cancer	0.000438	0.000455	CcSEcCtD
Methylphenidate—Eye disorder—Doxorubicin—urinary bladder cancer	0.000437	0.000454	CcSEcCtD
Methylphenidate—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000436	0.000453	CcSEcCtD
Methylphenidate—Anaemia—Methotrexate—urinary bladder cancer	0.000435	0.000451	CcSEcCtD
Methylphenidate—Flushing—Doxorubicin—urinary bladder cancer	0.000434	0.00045	CcSEcCtD
Methylphenidate—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000434	0.00045	CcSEcCtD
Methylphenidate—Tension—Epirubicin—urinary bladder cancer	0.000432	0.000448	CcSEcCtD
Methylphenidate—Nervousness—Epirubicin—urinary bladder cancer	0.000427	0.000443	CcSEcCtD
Methylphenidate—Back pain—Epirubicin—urinary bladder cancer	0.000426	0.000442	CcSEcCtD
Methylphenidate—Angiopathy—Doxorubicin—urinary bladder cancer	0.000424	0.00044	CcSEcCtD
Methylphenidate—Malaise—Methotrexate—urinary bladder cancer	0.000424	0.00044	CcSEcCtD
Methylphenidate—Dizziness—Etoposide—urinary bladder cancer	0.000424	0.00044	CcSEcCtD
Methylphenidate—Muscle spasms—Epirubicin—urinary bladder cancer	0.000423	0.000439	CcSEcCtD
Methylphenidate—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000423	0.000438	CcSEcCtD
Methylphenidate—Vertigo—Methotrexate—urinary bladder cancer	0.000422	0.000438	CcSEcCtD
Methylphenidate—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000422	0.000437	CcSEcCtD
Methylphenidate—Leukopenia—Methotrexate—urinary bladder cancer	0.000421	0.000437	CcSEcCtD
Methylphenidate—Chills—Doxorubicin—urinary bladder cancer	0.00042	0.000435	CcSEcCtD
Methylphenidate—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000418	0.000434	CcSEcCtD
Methylphenidate—Nausea—Cisplatin—urinary bladder cancer	0.000415	0.000431	CcSEcCtD
Methylphenidate—Vision blurred—Epirubicin—urinary bladder cancer	0.000415	0.00043	CcSEcCtD
Methylphenidate—Alopecia—Doxorubicin—urinary bladder cancer	0.000413	0.000429	CcSEcCtD
Methylphenidate—Cough—Methotrexate—urinary bladder cancer	0.00041	0.000426	CcSEcCtD
Methylphenidate—Mental disorder—Doxorubicin—urinary bladder cancer	0.00041	0.000425	CcSEcCtD
Methylphenidate—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000408	0.000424	CcSEcCtD
Methylphenidate—Convulsion—Methotrexate—urinary bladder cancer	0.000407	0.000423	CcSEcCtD
Methylphenidate—Vomiting—Etoposide—urinary bladder cancer	0.000407	0.000423	CcSEcCtD
Methylphenidate—Erythema—Doxorubicin—urinary bladder cancer	0.000407	0.000422	CcSEcCtD
Methylphenidate—Malnutrition—Doxorubicin—urinary bladder cancer	0.000407	0.000422	CcSEcCtD
Methylphenidate—Anaemia—Epirubicin—urinary bladder cancer	0.000407	0.000422	CcSEcCtD
Methylphenidate—Agitation—Epirubicin—urinary bladder cancer	0.000404	0.00042	CcSEcCtD
Methylphenidate—Rash—Etoposide—urinary bladder cancer	0.000404	0.000419	CcSEcCtD
Methylphenidate—Dermatitis—Etoposide—urinary bladder cancer	0.000404	0.000419	CcSEcCtD
Methylphenidate—Headache—Etoposide—urinary bladder cancer	0.000401	0.000416	CcSEcCtD
Methylphenidate—Arthralgia—Methotrexate—urinary bladder cancer	0.0004	0.000415	CcSEcCtD
Methylphenidate—Chest pain—Methotrexate—urinary bladder cancer	0.0004	0.000415	CcSEcCtD
Methylphenidate—Myalgia—Methotrexate—urinary bladder cancer	0.0004	0.000415	CcSEcCtD
Methylphenidate—Tension—Doxorubicin—urinary bladder cancer	0.0004	0.000415	CcSEcCtD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000398	0.000412	CcSEcCtD
Methylphenidate—Malaise—Epirubicin—urinary bladder cancer	0.000397	0.000412	CcSEcCtD
Methylphenidate—Discomfort—Methotrexate—urinary bladder cancer	0.000396	0.00041	CcSEcCtD
Methylphenidate—Nervousness—Doxorubicin—urinary bladder cancer	0.000395	0.00041	CcSEcCtD
Methylphenidate—Vertigo—Epirubicin—urinary bladder cancer	0.000395	0.00041	CcSEcCtD
Methylphenidate—Syncope—Epirubicin—urinary bladder cancer	0.000395	0.000409	CcSEcCtD
Methylphenidate—Leukopenia—Epirubicin—urinary bladder cancer	0.000394	0.000409	CcSEcCtD
Methylphenidate—Back pain—Doxorubicin—urinary bladder cancer	0.000394	0.000409	CcSEcCtD
Methylphenidate—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000391	0.000406	CcSEcCtD
Methylphenidate—Palpitations—Epirubicin—urinary bladder cancer	0.000389	0.000403	CcSEcCtD
Methylphenidate—Confusional state—Methotrexate—urinary bladder cancer	0.000387	0.000401	CcSEcCtD
Methylphenidate—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000387	0.000401	CcSEcCtD
Methylphenidate—Cough—Epirubicin—urinary bladder cancer	0.000384	0.000398	CcSEcCtD
Methylphenidate—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000384	0.000398	CcSEcCtD
Methylphenidate—Vision blurred—Doxorubicin—urinary bladder cancer	0.000384	0.000398	CcSEcCtD
Methylphenidate—Convulsion—Epirubicin—urinary bladder cancer	0.000381	0.000396	CcSEcCtD
Methylphenidate—Infection—Methotrexate—urinary bladder cancer	0.000381	0.000396	CcSEcCtD
Methylphenidate—Nausea—Etoposide—urinary bladder cancer	0.000381	0.000395	CcSEcCtD
Methylphenidate—Hypertension—Epirubicin—urinary bladder cancer	0.00038	0.000394	CcSEcCtD
Methylphenidate—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000378	0.000392	CcSEcCtD
Methylphenidate—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000376	0.00039	CcSEcCtD
Methylphenidate—Anaemia—Doxorubicin—urinary bladder cancer	0.000376	0.00039	CcSEcCtD
Methylphenidate—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000376	0.00039	CcSEcCtD
Methylphenidate—Myalgia—Epirubicin—urinary bladder cancer	0.000375	0.000389	CcSEcCtD
Methylphenidate—Arthralgia—Epirubicin—urinary bladder cancer	0.000375	0.000389	CcSEcCtD
Methylphenidate—Chest pain—Epirubicin—urinary bladder cancer	0.000375	0.000389	CcSEcCtD
Methylphenidate—Agitation—Doxorubicin—urinary bladder cancer	0.000374	0.000388	CcSEcCtD
Methylphenidate—Anxiety—Epirubicin—urinary bladder cancer	0.000373	0.000387	CcSEcCtD
Methylphenidate—Skin disorder—Methotrexate—urinary bladder cancer	0.000373	0.000387	CcSEcCtD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000372	0.000386	CcSEcCtD
Methylphenidate—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000371	0.000385	CcSEcCtD
Methylphenidate—Discomfort—Epirubicin—urinary bladder cancer	0.00037	0.000384	CcSEcCtD
Methylphenidate—Malaise—Doxorubicin—urinary bladder cancer	0.000367	0.000381	CcSEcCtD
Methylphenidate—Dry mouth—Epirubicin—urinary bladder cancer	0.000366	0.00038	CcSEcCtD
Methylphenidate—Vertigo—Doxorubicin—urinary bladder cancer	0.000366	0.00038	CcSEcCtD
Methylphenidate—Anorexia—Methotrexate—urinary bladder cancer	0.000366	0.00038	CcSEcCtD
Methylphenidate—Syncope—Doxorubicin—urinary bladder cancer	0.000365	0.000379	CcSEcCtD
Methylphenidate—Leukopenia—Doxorubicin—urinary bladder cancer	0.000364	0.000378	CcSEcCtD
Methylphenidate—Confusional state—Epirubicin—urinary bladder cancer	0.000362	0.000376	CcSEcCtD
Methylphenidate—Palpitations—Doxorubicin—urinary bladder cancer	0.00036	0.000373	CcSEcCtD
Methylphenidate—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000359	0.000373	CcSEcCtD
Methylphenidate—Oedema—Epirubicin—urinary bladder cancer	0.000359	0.000373	CcSEcCtD
Methylphenidate—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000358	0.000371	CcSEcCtD
Methylphenidate—Infection—Epirubicin—urinary bladder cancer	0.000357	0.00037	CcSEcCtD
Methylphenidate—Cough—Doxorubicin—urinary bladder cancer	0.000355	0.000369	CcSEcCtD
Methylphenidate—Shock—Epirubicin—urinary bladder cancer	0.000353	0.000367	CcSEcCtD
Methylphenidate—Convulsion—Doxorubicin—urinary bladder cancer	0.000353	0.000366	CcSEcCtD
Methylphenidate—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000352	0.000365	CcSEcCtD
Methylphenidate—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000352	0.000365	CcSEcCtD
Methylphenidate—Hypertension—Doxorubicin—urinary bladder cancer	0.000352	0.000365	CcSEcCtD
Methylphenidate—Tachycardia—Epirubicin—urinary bladder cancer	0.000351	0.000364	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.00035	0.000363	CcSEcCtD
Methylphenidate—Skin disorder—Epirubicin—urinary bladder cancer	0.000349	0.000362	CcSEcCtD
Methylphenidate—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000347	0.00036	CcSEcCtD
Methylphenidate—Insomnia—Methotrexate—urinary bladder cancer	0.000347	0.00036	CcSEcCtD
Methylphenidate—Chest pain—Doxorubicin—urinary bladder cancer	0.000347	0.00036	CcSEcCtD
Methylphenidate—Myalgia—Doxorubicin—urinary bladder cancer	0.000347	0.00036	CcSEcCtD
Methylphenidate—Arthralgia—Doxorubicin—urinary bladder cancer	0.000347	0.00036	CcSEcCtD
Methylphenidate—Anxiety—Doxorubicin—urinary bladder cancer	0.000345	0.000358	CcSEcCtD
Methylphenidate—Paraesthesia—Methotrexate—urinary bladder cancer	0.000345	0.000358	CcSEcCtD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000344	0.000357	CcSEcCtD
Methylphenidate—Discomfort—Doxorubicin—urinary bladder cancer	0.000343	0.000355	CcSEcCtD
Methylphenidate—Anorexia—Epirubicin—urinary bladder cancer	0.000342	0.000355	CcSEcCtD
Methylphenidate—Dyspnoea—Methotrexate—urinary bladder cancer	0.000342	0.000355	CcSEcCtD
Methylphenidate—Somnolence—Methotrexate—urinary bladder cancer	0.000341	0.000354	CcSEcCtD
Methylphenidate—Dry mouth—Doxorubicin—urinary bladder cancer	0.000339	0.000352	CcSEcCtD
Methylphenidate—SLC6A4—NRF2 pathway—NQO1—urinary bladder cancer	0.000338	0.00936	CbGpPWpGaD
Methylphenidate—Dyspepsia—Methotrexate—urinary bladder cancer	0.000338	0.00035	CcSEcCtD
Methylphenidate—Confusional state—Doxorubicin—urinary bladder cancer	0.000335	0.000348	CcSEcCtD
Methylphenidate—Decreased appetite—Methotrexate—urinary bladder cancer	0.000334	0.000346	CcSEcCtD
Methylphenidate—Oedema—Doxorubicin—urinary bladder cancer	0.000332	0.000345	CcSEcCtD
Methylphenidate—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000332	0.000345	CcSEcCtD
Methylphenidate—SLC6A4—Monoamine Transport—TNF—urinary bladder cancer	0.000332	0.0092	CbGpPWpGaD
Methylphenidate—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000331	0.000344	CcSEcCtD
Methylphenidate—Fatigue—Methotrexate—urinary bladder cancer	0.000331	0.000343	CcSEcCtD
Methylphenidate—Infection—Doxorubicin—urinary bladder cancer	0.00033	0.000343	CcSEcCtD
Methylphenidate—Pain—Methotrexate—urinary bladder cancer	0.000328	0.00034	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000327	0.000339	CcSEcCtD
Methylphenidate—Shock—Doxorubicin—urinary bladder cancer	0.000327	0.000339	CcSEcCtD
Methylphenidate—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000326	0.000338	CcSEcCtD
Methylphenidate—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000325	0.000338	CcSEcCtD
Methylphenidate—Insomnia—Epirubicin—urinary bladder cancer	0.000325	0.000337	CcSEcCtD
Methylphenidate—Tachycardia—Doxorubicin—urinary bladder cancer	0.000324	0.000336	CcSEcCtD
Methylphenidate—Skin disorder—Doxorubicin—urinary bladder cancer	0.000323	0.000335	CcSEcCtD
Methylphenidate—Paraesthesia—Epirubicin—urinary bladder cancer	0.000323	0.000335	CcSEcCtD
Methylphenidate—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000321	0.000333	CcSEcCtD
Methylphenidate—Dyspnoea—Epirubicin—urinary bladder cancer	0.00032	0.000332	CcSEcCtD
Methylphenidate—Somnolence—Epirubicin—urinary bladder cancer	0.000319	0.000331	CcSEcCtD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—ESR2—urinary bladder cancer	0.000318	0.00881	CbGpPWpGaD
Methylphenidate—Anorexia—Doxorubicin—urinary bladder cancer	0.000317	0.000329	CcSEcCtD
Methylphenidate—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000316	0.000328	CcSEcCtD
Methylphenidate—Dyspepsia—Epirubicin—urinary bladder cancer	0.000316	0.000328	CcSEcCtD
Methylphenidate—CYP2D6—Biological oxidations—GSTZ1—urinary bladder cancer	0.000316	0.00876	CbGpPWpGaD
Methylphenidate—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000314	0.000326	CcSEcCtD
Methylphenidate—Decreased appetite—Epirubicin—urinary bladder cancer	0.000312	0.000324	CcSEcCtD
Methylphenidate—CYP2D6—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000312	0.00864	CbGpPWpGaD
Methylphenidate—SLC6A3—Alpha-synuclein signaling—SRC—urinary bladder cancer	0.000311	0.00861	CbGpPWpGaD
Methylphenidate—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.00031	0.000322	CcSEcCtD
Methylphenidate—Fatigue—Epirubicin—urinary bladder cancer	0.00031	0.000321	CcSEcCtD
Methylphenidate—Pain—Epirubicin—urinary bladder cancer	0.000307	0.000319	CcSEcCtD
Methylphenidate—Constipation—Epirubicin—urinary bladder cancer	0.000307	0.000319	CcSEcCtD
Methylphenidate—Urticaria—Methotrexate—urinary bladder cancer	0.000305	0.000316	CcSEcCtD
Methylphenidate—Abdominal pain—Methotrexate—urinary bladder cancer	0.000303	0.000315	CcSEcCtD
Methylphenidate—Body temperature increased—Methotrexate—urinary bladder cancer	0.000303	0.000315	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000303	0.000314	CcSEcCtD
Methylphenidate—Insomnia—Doxorubicin—urinary bladder cancer	0.000301	0.000312	CcSEcCtD
Methylphenidate—CYP2D6—Biological oxidations—GSTO2—urinary bladder cancer	0.0003	0.0083	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—NAT1—urinary bladder cancer	0.0003	0.0083	CbGpPWpGaD
Methylphenidate—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000298	0.00031	CcSEcCtD
Methylphenidate—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000296	0.000307	CcSEcCtD
Methylphenidate—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000296	0.000307	CcSEcCtD
Methylphenidate—CYP2D6—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000296	0.00819	CbGpPWpGaD
Methylphenidate—Somnolence—Doxorubicin—urinary bladder cancer	0.000295	0.000307	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000294	0.000305	CcSEcCtD
Methylphenidate—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000293	0.000303	CcSEcCtD
Methylphenidate—SLC6A2—NRF2 pathway—NQO1—urinary bladder cancer	0.000291	0.00805	CbGpPWpGaD
Methylphenidate—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000289	0.0003	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000287	0.000298	CcSEcCtD
Methylphenidate—Fatigue—Doxorubicin—urinary bladder cancer	0.000287	0.000297	CcSEcCtD
Methylphenidate—SLC6A2—Monoamine Transport—TNF—urinary bladder cancer	0.000286	0.00791	CbGpPWpGaD
Methylphenidate—Urticaria—Epirubicin—urinary bladder cancer	0.000285	0.000296	CcSEcCtD
Methylphenidate—Pain—Doxorubicin—urinary bladder cancer	0.000284	0.000295	CcSEcCtD
Methylphenidate—Constipation—Doxorubicin—urinary bladder cancer	0.000284	0.000295	CcSEcCtD
Methylphenidate—Body temperature increased—Epirubicin—urinary bladder cancer	0.000284	0.000295	CcSEcCtD
Methylphenidate—Abdominal pain—Epirubicin—urinary bladder cancer	0.000284	0.000295	CcSEcCtD
Methylphenidate—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000283	0.000293	CcSEcCtD
Methylphenidate—SLC6A4—NRF2 pathway—GSTP1—urinary bladder cancer	0.000282	0.00781	CbGpPWpGaD
Methylphenidate—Asthenia—Methotrexate—urinary bladder cancer	0.000275	0.000286	CcSEcCtD
Methylphenidate—CYP2D6—Biological oxidations—UGT2B7—urinary bladder cancer	0.000274	0.00759	CbGpPWpGaD
Methylphenidate—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000274	0.000284	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000272	0.000282	CcSEcCtD
Methylphenidate—Pruritus—Methotrexate—urinary bladder cancer	0.000272	0.000282	CcSEcCtD
Methylphenidate—CYP2D6—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.00027	0.00749	CbGpPWpGaD
Methylphenidate—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000265	0.000275	CcSEcCtD
Methylphenidate—Urticaria—Doxorubicin—urinary bladder cancer	0.000264	0.000274	CcSEcCtD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000264	0.0073	CbGpPWpGaD
Methylphenidate—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000263	0.000273	CcSEcCtD
Methylphenidate—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000263	0.000273	CcSEcCtD
Methylphenidate—Diarrhoea—Methotrexate—urinary bladder cancer	0.000263	0.000272	CcSEcCtD
Methylphenidate—SLC6A4—NRF2 pathway—GSTM1—urinary bladder cancer	0.000259	0.00718	CbGpPWpGaD
Methylphenidate—Asthenia—Epirubicin—urinary bladder cancer	0.000258	0.000267	CcSEcCtD
Methylphenidate—SLC6A3—NRF2 pathway—NQO1—urinary bladder cancer	0.000258	0.00713	CbGpPWpGaD
Methylphenidate—Pruritus—Epirubicin—urinary bladder cancer	0.000254	0.000264	CcSEcCtD
Methylphenidate—Dizziness—Methotrexate—urinary bladder cancer	0.000254	0.000263	CcSEcCtD
Methylphenidate—SLC6A3—Monoamine Transport—TNF—urinary bladder cancer	0.000253	0.00701	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—CYP4B1—urinary bladder cancer	0.000247	0.00684	CbGpPWpGaD
Methylphenidate—Diarrhoea—Epirubicin—urinary bladder cancer	0.000246	0.000255	CcSEcCtD
Methylphenidate—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000245	0.000254	CcSEcCtD
Methylphenidate—Vomiting—Methotrexate—urinary bladder cancer	0.000244	0.000253	CcSEcCtD
Methylphenidate—CYP2D6—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000243	0.00674	CbGpPWpGaD
Methylphenidate—SLC6A2—NRF2 pathway—GSTP1—urinary bladder cancer	0.000242	0.00672	CbGpPWpGaD
Methylphenidate—Rash—Methotrexate—urinary bladder cancer	0.000242	0.000251	CcSEcCtD
Methylphenidate—Dermatitis—Methotrexate—urinary bladder cancer	0.000242	0.000251	CcSEcCtD
Methylphenidate—Headache—Methotrexate—urinary bladder cancer	0.00024	0.000249	CcSEcCtD
Methylphenidate—Asthenia—Doxorubicin—urinary bladder cancer	0.000238	0.000247	CcSEcCtD
Methylphenidate—Dizziness—Epirubicin—urinary bladder cancer	0.000238	0.000246	CcSEcCtD
Methylphenidate—Pruritus—Doxorubicin—urinary bladder cancer	0.000235	0.000244	CcSEcCtD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000234	0.00647	CbGpPWpGaD
Methylphenidate—Vomiting—Epirubicin—urinary bladder cancer	0.000228	0.000237	CcSEcCtD
Methylphenidate—Nausea—Methotrexate—urinary bladder cancer	0.000228	0.000237	CcSEcCtD
Methylphenidate—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000227	0.000236	CcSEcCtD
Methylphenidate—Rash—Epirubicin—urinary bladder cancer	0.000226	0.000235	CcSEcCtD
Methylphenidate—Dermatitis—Epirubicin—urinary bladder cancer	0.000226	0.000235	CcSEcCtD
Methylphenidate—Headache—Epirubicin—urinary bladder cancer	0.000225	0.000233	CcSEcCtD
Methylphenidate—SLC6A2—NRF2 pathway—GSTM1—urinary bladder cancer	0.000223	0.00617	CbGpPWpGaD
Methylphenidate—Dizziness—Doxorubicin—urinary bladder cancer	0.00022	0.000228	CcSEcCtD
Methylphenidate—SLC6A3—NRF2 pathway—GSTP1—urinary bladder cancer	0.000215	0.00595	CbGpPWpGaD
Methylphenidate—Nausea—Epirubicin—urinary bladder cancer	0.000213	0.000221	CcSEcCtD
Methylphenidate—Vomiting—Doxorubicin—urinary bladder cancer	0.000211	0.000219	CcSEcCtD
Methylphenidate—Rash—Doxorubicin—urinary bladder cancer	0.00021	0.000217	CcSEcCtD
Methylphenidate—Dermatitis—Doxorubicin—urinary bladder cancer	0.000209	0.000217	CcSEcCtD
Methylphenidate—Headache—Doxorubicin—urinary bladder cancer	0.000208	0.000216	CcSEcCtD
Methylphenidate—SLC6A4—Circadian rythm related genes—TYMS—urinary bladder cancer	0.000203	0.00562	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—NCOR1—urinary bladder cancer	0.000201	0.00556	CbGpPWpGaD
Methylphenidate—Nausea—Doxorubicin—urinary bladder cancer	0.000197	0.000205	CcSEcCtD
Methylphenidate—SLC6A3—NRF2 pathway—GSTM1—urinary bladder cancer	0.000197	0.00547	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000191	0.00528	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—FAS—urinary bladder cancer	0.00018	0.00498	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	0.000169	0.00469	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000169	0.00468	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—NAT2—urinary bladder cancer	0.000164	0.00455	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000162	0.00449	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—CDK4—urinary bladder cancer	0.000158	0.00438	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000155	0.0043	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—PPARG—urinary bladder cancer	0.000144	0.00398	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000138	0.00381	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	0.000134	0.00372	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—HPGDS—urinary bladder cancer	0.000131	0.00364	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—GSTT1—urinary bladder cancer	0.000127	0.00353	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	0.000115	0.00319	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000105	0.00291	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—PTEN—urinary bladder cancer	9.86e-05	0.00273	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—EP300—urinary bladder cancer	9.41e-05	0.00261	CbGpPWpGaD
Methylphenidate—SLC6A4—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	9.35e-05	0.00259	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	9.3e-05	0.00258	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—GSTP1—urinary bladder cancer	8.82e-05	0.00244	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—GSTP1—urinary bladder cancer	8.7e-05	0.00241	CbGpPWpGaD
Methylphenidate—CYP2D6—Biological oxidations—GSTM1—urinary bladder cancer	8.11e-05	0.00225	CbGpPWpGaD
Methylphenidate—CYP2D6—Metapathway biotransformation—GSTM1—urinary bladder cancer	8e-05	0.00222	CbGpPWpGaD
Methylphenidate—SLC6A4—Circadian rythm related genes—TP53—urinary bladder cancer	6.73e-05	0.00186	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	5.41e-05	0.0015	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	5.12e-05	0.00142	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—NAT1—urinary bladder cancer	5.12e-05	0.00142	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	4.92e-05	0.00136	CbGpPWpGaD
Methylphenidate—SLC6A2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	4.91e-05	0.00136	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	4.69e-05	0.0013	CbGpPWpGaD
Methylphenidate—SLC6A3—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	4.35e-05	0.00121	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	4.22e-05	0.00117	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	3.99e-05	0.0011	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	3.88e-05	0.00108	CbGpPWpGaD
Methylphenidate—SLC6A3—Neuronal System—HRAS—urinary bladder cancer	3.77e-05	0.00104	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—TYMP—urinary bladder cancer	3.1e-05	0.00086	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—NAT2—urinary bladder cancer	2.81e-05	0.000778	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—RRM2—urinary bladder cancer	2.42e-05	0.000671	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ENO2—urinary bladder cancer	2.24e-05	0.000622	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	2.24e-05	0.000622	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	2.18e-05	0.000603	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—NQO1—urinary bladder cancer	1.81e-05	0.000501	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	1.51e-05	0.000418	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—TYMS—urinary bladder cancer	1.4e-05	0.000389	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	1.39e-05	0.000384	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	1.39e-05	0.000384	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—GPX1—urinary bladder cancer	1.33e-05	0.000368	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	1.3e-05	0.000361	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	1.23e-05	0.000339	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PPARG—urinary bladder cancer	9.94e-06	0.000275	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	9.55e-06	0.000264	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	7.82e-06	0.000217	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—PTEN—urinary bladder cancer	6.82e-06	0.000189	CbGpPWpGaD
Methylphenidate—CYP2D6—Metabolism—EP300—urinary bladder cancer	6.5e-06	0.00018	CbGpPWpGaD
